Polydex Pharmaceuticals Announces Appointment of Martin Lipper to Board of Directors
July 07 2010 - 10:24AM
Polydex Pharmaceuticals Limited (Pink
Sheets:POLXF) (the "Company") is pleased to announce the
appointment of Mr. Martin Lipper to the Board of Directors.
Mr. Lipper brings extensive Wall Street expertise to the Board,
and has wide-ranging experience in business development, financing,
mergers and acquisitions, and operations management.
Mr. Lipper has long been associated with the company, as a
shareholder, financier, analyst and investment broker, and as such
has in-depth knowledge of the Company's financials, business model,
history and potential going forward.
George Usher, President and CEO of the Company, said, "Mr.
Lipper is the ideal person to join our Board, especially at this
time of transition in the public marketplace. He is very familiar
with our line of products, our domestic and overseas sales markets,
our management, and the company's position in the public market,
and as such is sure to be an invaluable asset to the Board. We
are very happy he has accepted this position on our Board of
Directors."
The company also announces the retirement of John L.E. Seidler
from its Board of Directors. Management would like to
thank Mr. Seidler for bringing his expertise to Polydex, and for
his years of service to the Company.
The Company shares continue to be quoted and traded on the Pink
Sheet platform (www.pinksheets.com).
Polydex Pharmaceuticals Limited, based in Toronto, Ontario,
Canada, is engaged in the development, manufacture and marketing of
biotechnology-based products for the human pharmaceutical market,
and also manufactures bulk pharmaceutical intermediates for the
worldwide veterinary pharmaceutical industry. Company website:
www.Polydex.com
The Polydex Pharmaceuticals Limited logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3414
Note: This press release may contain forward-looking
statements, within the meaning of the United States Securities Act
of 1933, as amended, and the United States Securities Exchange Act
of 1934, as amended, regarding Polydex Pharmaceuticals Limited,
including, without limitation, statements regarding expectations
about future revenues or business opportunities or potential
research projects. These statements are typically identified by use
of words like "may," "could," "might," "expect," "anticipate,"
"believe," or similar words. Actual events or results may differ
materially from the Company's expectations, which are subject to a
number of known and unknown risks and uncertainties including but
not limited to changing market conditions, future actions by the
United States Food and Drug Administration or equivalent foreign
regulatory authorities as results of pending or future clinical
trials. Other risk factors discussed in the Company's filings with
the United States Securities and Exchange Commission may also
affect the actual results achieved by the Company.
CONTACT: North Arm Capital Services
Investor Relations:
Linda Hughes
1-877-945-1621
Linda@northarm.com
Polydex Pharmaceuticals (PK) (USOTC:POLXF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Polydex Pharmaceuticals (PK) (USOTC:POLXF)
Historical Stock Chart
From Jul 2023 to Jul 2024